Véronique Leblond

14.7k total citations
218 papers, 7.2k citations indexed

About

Véronique Leblond is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Véronique Leblond has authored 218 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 133 papers in Genetics, 104 papers in Pathology and Forensic Medicine and 52 papers in Immunology. Recurrent topics in Véronique Leblond's work include Chronic Lymphocytic Leukemia Research (121 papers), Lymphoma Diagnosis and Treatment (99 papers) and Immunodeficiency and Autoimmune Disorders (41 papers). Véronique Leblond is often cited by papers focused on Chronic Lymphocytic Leukemia Research (121 papers), Lymphoma Diagnosis and Treatment (99 papers) and Immunodeficiency and Autoimmune Disorders (41 papers). Véronique Leblond collaborates with scholars based in France, Germany and United States. Véronique Leblond's co-authors include Sylvain Choquet, Jean‐Paul Fermand, Steven P. Treon, François Dreyfus, Olivier Hermine, Meletios Α. Dimopoulos, Sylvie Chevret, Arnaud Jaccard, Marine Diviné and Giampaolo Merlini and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Véronique Leblond

209 papers receiving 7.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Véronique Leblond France	43	3.1k	3.1k	2.5k	2.1k	1.8k	218	7.2k
Michinori Ogura Japan	43	3.2k 1.0×	1.8k 0.6×	3.0k 1.2×	1.5k 0.7×	1.2k 0.7×	223	7.3k
Pierluigi Porcu United States	42	2.8k 0.9×	1.3k 0.4×	2.7k 1.1×	1.1k 0.5×	1.8k 1.0×	289	7.1k
Arnold S. Freedman United States	50	3.8k 1.2×	2.5k 0.8×	3.4k 1.4×	1.9k 0.9×	1.8k 1.0×	188	9.7k
Pier Paolo Piccaluga Italy	40	2.7k 0.9×	1.2k 0.4×	2.1k 0.8×	1.2k 0.6×	1.3k 0.7×	208	5.8k
Lubomir Sokol United States	37	2.0k 0.6×	1.4k 0.5×	1.8k 0.7×	1.3k 0.6×	1.3k 0.7×	269	5.3k
Ioannis Anagnostopoulos Germany	44	3.3k 1.1×	1.1k 0.4×	3.4k 1.3×	887 0.4×	1.4k 0.8×	136	7.8k
Philip M. Kluin Netherlands	47	3.1k 1.0×	1.5k 0.5×	2.3k 0.9×	858 0.4×	1.3k 0.7×	130	6.8k
Arnaud Jaccard France	39	1.2k 0.4×	1.6k 0.5×	1.8k 0.7×	1.4k 0.6×	3.3k 1.9×	205	6.1k
Auayporn Nademanee United States	39	3.2k 1.0×	1.3k 0.4×	3.3k 1.3×	3.1k 1.5×	603 0.3×	180	7.3k
Elizabeth Macintyre France	44	2.0k 0.6×	1.4k 0.4×	1.5k 0.6×	2.8k 1.3×	1.9k 1.1×	237	7.7k

Countries citing papers authored by Véronique Leblond

Since Specialization

Citations

This map shows the geographic impact of Véronique Leblond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Véronique Leblond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Véronique Leblond more than expected).

Fields of papers citing papers by Véronique Leblond

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Véronique Leblond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Véronique Leblond. The network helps show where Véronique Leblond may publish in the future.

Co-authorship network of co-authors of Véronique Leblond

This figure shows the co-authorship network connecting the top 25 collaborators of Véronique Leblond. A scholar is included among the top collaborators of Véronique Leblond based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Véronique Leblond. Véronique Leblond is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sourdeau, Élise, Aurélien Corneau, Myrto Costopoulos, et al.. (2025). Phenotypic Profile of Waldenström Macroglobulinaemia B‐Cells: Establishment of a Diagnosis Scoring System and Clinico‐Biological Correlations. Journal of Cellular and Molecular Medicine. 29(10). e70620–e70620.

Laribi, Kamel, Stéphanie Poulain, Lise Willems, et al.. (2024). Long‐term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO). British Journal of Haematology. 204(6). 2233–2236. 6 indexed citations

Leblond, Véronique, et al.. (2023). Investigation and Management of Immunoglobulin M– and Waldenström-Associated Peripheral Neuropathies. Hematology/Oncology Clinics of North America. 37(4). 761–776. 1 indexed citations

Baptiste, Amandine, Lisa Belin, Pascale Ghillani‐Dalbin, et al.. (2022). Immunochemotherapy versus rituximab in anti‐myelin‐associated glycoprotein neuropathy: A report of 64 patients. British Journal of Haematology. 198(2). 298–306. 4 indexed citations

Chami, L., Alain Giron, Véronique Leblond, et al.. (2021). Quantitative and Qualitative Approach for Shear Wave Elastography in Superficial Lymph Nodes. Ultrasound in Medicine & Biology. 47(8). 2117–2127. 11 indexed citations

Roos‐Weil, Damien, Nicolas Weiss, Amélie Guihot, et al.. (2021). Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: a new gold standard?. Journal of Neurology. 268(7). 2458–2465. 11 indexed citations

Tomowiak, Cécile, Stéphanie Poulain, Charles Herbaux, et al.. (2021). Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia. Blood Advances. 5(9). 2438–2446. 21 indexed citations

Maffini, Enrico, Myriam Labopin, Didier Blaise, et al.. (2020). CD34+ cell dose effects on clinical outcomes after T‐cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (EBMT). American Journal of Hematology. 95(8). 892–899. 22 indexed citations

Roos‐Weil, Damien, Brian Giacopelli, Marine Armand, et al.. (2020). Identification of two DNA methylation subtypes of Waldenström's macroglobulinemia with plasma and memory B cell features. Blood. 136(5). 585–595. 6 indexed citations

10.

Baron, Marine, Laurence Simon, Stéphanie Poulain, & Véronique Leblond. (2019). How Recent Advances in Biology of Waldenström’s Macroglobulinemia May Affect Therapy Strategy. Current Oncology Reports. 21(3). 27–27. 3 indexed citations

11.

Bosch, Francesc, Guy Cantin, Agostino Cortelezzi, et al.. (2019). Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study. Leukemia. 34(2). 441–450. 6 indexed citations

12.

D’Sa, Shirley, Marie José Kersten, Jorge J. Castillo, et al.. (2017). Investigation and management of IgM and Waldenström‐associated peripheral neuropathies: recommendations from the IWWM ‐8 consensus panel. British Journal of Haematology. 176(5). 728–742. 47 indexed citations

13.

Costopoulos, Myrto, Rathana Kim, Sylvain Choquet, et al.. (2017). Cerebrospinal fluid interleukin (IL)-10 and IL-10:IL-6 ratio as biomarkers for small B-cell lymphoproliferations with leptomeningeal dissemination. Seminars in Hematology. 55(4). 179–181. 5 indexed citations

14.

Cornet, Édouard, Cécile Tomowiak, Aline Schmidt, et al.. (2014). Long‐term follow‐up and second malignancies in 487 patients with hairy cell leukaemia. British Journal of Haematology. 166(3). 390–400. 42 indexed citations

15.

Terrier, Benjamin, Alexandre Karras, Jean‐Emmanuel Kahn, et al.. (2013). The Spectrum of Type I Cryoglobulinemia Vasculitis. Medicine. 92(2). 61–68. 125 indexed citations

16.

Leprêtre, Stéphane, Ann Janssens, Véronique Leblond, et al.. (2011). The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature. Leukemia & lymphoma. 53(5). 820–829. 4 indexed citations

17.

Moreau, Philippe, Arnaud Jaccard, Lotfi Benboubker, et al.. (2010). Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood. 116(23). 4777–4782. 96 indexed citations

18.

Morel, Pierre, Alain Duhamel, Paolo G. Gobbi, et al.. (2009). International prognostic scoring system for Waldenström macroglobulinemia. Blood. 113(18). 4163–4170. 228 indexed citations

19.

Leleu, Xavier, Jérôme Tamburini, Aldo M. Roccaro, et al.. (2009). Balancing Risk Versus Benefit in the Treatment of Waldenström's Macroglobulinemia Patients with Nucleoside Analogue–Based Therapy. Clinical Lymphoma & Myeloma. 9(1). 71–73. 20 indexed citations

20.

Trappe, Ralf Ulrich, Sylvain Choquet, Petra Reinke, et al.. (2007). Salvage Therapy for Relapsed Posttransplant Lymphoproliferative Disorders (PTLD) With a Second Progression of PTLD After Upfront Chemotherapy: The Role of Single-Agent Rituximab. Transplantation. 84(12). 1708–1712. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact